An Analysis of the Use of Dogs in Predicting Human Toxicology and Drug Safety
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Dogs remain the main non-rodent species in preclinical drug development. Despite the current dearth of new drug approvals and meagre pipelines, this continues, with little supportive evidence of its value or necessity. To estimate the evidential weight provided by canine data to the probability that a new drug may be toxic to humans, we have calculated Likelihood Ratios (LRs) for an extensive dataset of 2,366 drugs with both animal and human data, including tissue-level effects and Medical Dictionary for Regulatory Activities (MedDRA) Level 1-4 biomedical observations. The resulting LRs show that the absence of toxicity in dogs provides virtually no evidence that adverse drug reactions (ADRs) will also be absent in humans. While the LRs suggest that the presence of toxic effects in dogs can provide considerable evidential weight for a risk of potential ADRs in humans, this is highly inconsistent, varying by over two orders of magnitude for different classes of compounds and their effects. Our results therefore have important implications for the value of the dog in predicting human toxicity, and suggest that alternative methods are urgently required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The investigators also examined canine models and found that PPV and PLR for human toxicity were not correlated with 1 another: NLR were low, indicating that the dog provided little evidentiary weight to ruling out toxicity in humans (52).”
From Limitations of Animal Studies for Predicting Toxicity in Clinical Trials (2019) · cites this paper as [52]
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Statistics Notes: Diagnostic tests 2: predictive values
Altman, D. G., & Bland, J. M. (1994) · BMJ · doi:10.1136/bmj.309.6947.102 · Cited by 1,711
Can Animal Models of Disease Reliably Inform Human Studies?
van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O'Collins, V., & Macleod, M. R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000245 · Cited by 1,354
Left Ventricular Hypertrophy: Pathogenesis, Detection, and Prognosis
Lorell, B. H., & Carabello, B. A. (2000) · Circulation · doi:10.1161/01.cir.102.4.470 · Cited by 1,232
The Domestication of Social Cognition in Dogs
Hare, B., Brown, M., Williamson, C., & Tomasello, M. (2002) · Science · doi:10.1126/science.1072702 · Cited by 1,046
Kilkenny, C., Parsons, N., Kadyszewski, E., Festing, M. F. W., Cuthill, I. C., Fry, D., Hutton, J., & Altman, D. G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007824 · Cited by 860
Refining clinical diagnosis with likelihood ratios
Grimes, D. A., & Schulz, K. F. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66422-7 · Cited by 828
Comparison of Treatment Effects between Animal Experiments and Clinical Trials: Systematic Review
Perel, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, P., Macleod, M., Mignini, L. E., Jayaram, P., & Khan, K. S. (2007) · BMJ · doi:10.1136/bmj.39048.407928.be · Cited by 827
Russell, D. W., & Setchell, K. D. R. (1992) · Biochemistry · doi:10.1021/bi00135a001 · Cited by 819
Toxicology for the twenty-first century
Hartung, T. (2009) · Nature · doi:10.1038/460208a · Cited by 661
Publication bias in reports of animal stroke studies leads to major overstatement of efficacy
Sena, E. S., van der Worp, H. B., Bath, P. M. W., Howells, D. W., & Macleod, M. R. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000344 · Cited by 600
(2006) · CRC Press eBooks · doi:10.1201/9781420014204 · Cited by 301
Chirinos, J. A., Segers, P., De Buyzere, M. L., Kronmal, R. A., Raja, M. W., De Bacquer, D., Claessens, T., Gillebert, T. C., St. John-Sutton, M., & Rietzschel, E. R. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.150250 · Cited by 259
Systematic reviews of animal models: methodology versus epistemology
Greek, R., & Menache, A. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.5529 · Cited by 207
Fourches, D., Barnes, J. C., Day, N. C., Bradley, P., Reed, J. Z., & Tropsha, A. (2010) · Chemical Research in Toxicology · doi:10.1021/tx900326k · Cited by 162
Leikauf, G. D., McDowell, S. A., Wesselkamper, S. C., Hardie, W. D., Leikauf, J. E., Korfhagen, T. R., & Prows, D. R. (2002) · Chest · doi:10.1378/chest.121.3_suppl.70s · Cited by 160
Translating animal research into clinical benefit
Hackam, D. G. (2007) · BMJ · doi:10.1136/bmj.39104.362951.80 · Cited by 157
Signs and Symptoms: Zeroing in on a better classification of neuroses
Colby, K. M., & McGuire, M. T. (1981) · The Sciences · doi:10.1002/j.2326-1951.1981.tb02013.x · Cited by 149
Drug discovery in the next decade: innovation needed ASAP
Bennani, Y. L. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.004 · Cited by 133
Medical progress depends on animal models - doesn't it?
Matthews, R. A. (2008) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2007.070164 · Cited by 132
ter Riet, G., Korevaar, D. A., Leenaars, M., Sterk, P. J., Van Noorden, C. J. F., Bouter, L. M., Lutter, R., Elferink, R. P. O., & Hooft, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043404 · Cited by 131
Roman, G. T., Walsh, T. J., & Massie, E. (1961) · The American Journal of Cardiology · doi:10.1016/0002-9149(61)90504-5 · Cited by 113
The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences
Schott, G., Pachl, H., Limbach, U., Gundert-Remy, U., Ludwig, W.-D., & Lieb, K. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0279 · Cited by 101
2007 FDA drug approvals: a year of flux
Hughes, B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2514 · Cited by 92
Statistics of Scientific Procedures on living animals, Great Britain 2011
Carter, E. (2012) · Animal Welfare · doi:10.1017/s0962728600004280 · Cited by 92
Duyk, G. (2003) · Science · doi:10.1126/science.1090521 · Cited by 87
Access before Approval — A Right to Take Experimental Drugs?
Okie, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068132 · Cited by 76
Predictability of clinical adverse reactions of drugs by general pharmacology studies.
Igarashi, T., NAKANE, S., & Kitagawa, T. (1995) · The Journal of Toxicological Sciences · doi:10.2131/jts.20.77 · Cited by 74
Critical evaluation of the use of dogs in biomedical research and testing in Europe
Hasiwa, N. (2011) · ALTEX · doi:10.14573/altex.2011.4.326 · Cited by 74
Self-citationPulmonary vascular resistance: A meaningless variable
Versprille, A. (1984) · Intensive Care Medicine · doi:10.1007/bf00297557 · Cited by 74
The ability of animal studies to detect serious post marketing adverse events is limited
van Meer, P. J. K., Kooijman, M., Gispen-de Wied, C. C., Moors, E. H. M., & Schellekens, H. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.09.002 · Cited by 66
Adams, L. G., & Polzin, D. J. (1989) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/s0195-5616(89)50032-9 · Cited by 63
Martinez, M. N., Antonovic, L., Court, M., Dacasto, M., Fink-Gremmels, J., Kukanich, B., Locuson, C., Mealey, K., Myers, M. J., & Trepanier, L. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.765445 · Cited by 62
Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends
Issa, A., Phillips, K., Van Bebber, S., Nidamarthy, H., Lasser, K., Haas, J., Alldredge, B., Wachter, R., & Bates, D. (2007) · Current Drug Safety · doi:10.2174/157488607781668855 · Cited by 59
Part XVI. Evaluation of the safety of new drugs by means of tests in animals
Litchfield, J. T. (1962) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196235665 · Cited by 59
Wandall, B., Hansson, S. O., & Rudén, C. (2007) · Archives of Toxicology · doi:10.1007/s00204-007-0194-5 · Cited by 48
New drug approval success rate in Europe in 2009
Eichler, H., Aronsson, B., Abadie, E., & Salmonson, T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3169 · Cited by 46
Publication bias in animal research: a systematic review protocol
Briel, M., Müller, K. F., Meerpohl, J. J., von Elm, E., Lang, B., Motschall, E., Gloy, V., Lamontagne, F., Schwarzer, G., & Bassler, D. (2013) · Systematic Reviews · doi:10.1186/2046-4053-2-23 · Cited by 36
Broadhead, C. L., Betton, G. R., Combes, R. D., Damment, S. J. P., Everett, D. J., Garner, C., Godsafe, Z., Healing, G., Heywood, R. L., Jennings, M., et al. (2000) · Human & Experimental Toxicology · doi:10.1191/096032700682694242 · Cited by 35
Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation
Greco, I., Day, N., Riddoch-Contreras, J., Reed, J., Soininen, H., Kłoszewska, I., Tsolaki, M., Vellas, B., Spenger, C., Mecocci, P., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-217 · Cited by 31
Jörres, A., & Frei, U. A. (2001) · Der Internist · doi:10.1007/s001080050765 · Cited by 28
Symposium on clinical drug evaluation and human pharmacology
Rinzler, S. H. (1962) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196234505 · Cited by 22
Bedford, D. E. (1939) · The Lancet · doi:10.1016/s0140-6736(00)76254-4 · Cited by 21
Developmental Toxicity Testing: Protecting Future Generations?
Bailey, J. (2008) · Alternatives to Laboratory Animals · doi:10.1177/026119290803600618 · Cited by 16
Self-citationPride, H. (2008) · Pediatric Dermatology · doi:10.1016/b978-0-7020-3022-2.10004-0 · Cited by 15
Gordon, J. L., & Miichinson, M. J. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92638-5 · Cited by 6
Glaucoma and ocular hypertension.
Mh, L. (1972) · PubMed · Cited by 6
A kidney.Glomerulonephritis and nephrotic syndrome.
Arakawa, M. (1991) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.80.488 · Cited by 4
Dubach, U. C. (1972) · PubMed · Cited by 2
Jondeau, G., & Détaint, D. (2008) · PubMed · Cited by 2
Schardein, J. L. (2000) · CRC Press eBooks · doi:10.3109/9780203909904-34 · Cited by 2
Central Nervous System Vascular Disorders
Lewena, S., & Babl, F. E. (2008) · Elsevier eBooks · doi:10.1016/b978-141600087-7.50047-7 · Cited by 1
Research works printed but not linked: 10
- Anon., 2004, Official Journal of the European Union L136, 34
- Aithal G.P., 2010, ATLA, 38, 1
- Anon. (2012). Likelihood Ratios. Oxford, UK: Centre for Evidence Based Medicine (CEBM). Available at: http://www.cebm.net/index.aspx?o=1043 (Accessed 10.10.13).
- Bailey J., 2008, ATLA, 36, 718
- SpanhaakS., CookD., BarnesJ. & ReynoldsJ. (2008). Species Concordance for Liver Injury, 6pp. Cambridge, UK: Biowisdom Ltd. Available at: http://www.biowisdom.com/files/SIP_Board_Species_Concordance.pdf (Accessed 10.10.13).
- BarnesJ.C., MatisS., KennaG., SwintonJ., BradleyP.M., DayN.C., ReedJ.Z., ReynoldsJ. & CookD. (2008). The Safety Intelligence Program: An Intelligence Network for Drug-induced Liver Injury, 2pp. Cambridge, UK: Biowisdom Ltd. Available at: http://bioblog.instem.com/downloads/Carboxylic_acids_A4.pdf (Accessed 10.10.13).
- Schott G., 2010, Deutsches Arzteblatt International, 107, 279
- Anon., 2010, Official Journal of the European Union L276, 33
- Anon. (1990). FDA Drug Review: Post Approval Risks 1976–1985. GAO/PEMD-90-15, 132pp. Washington, DC, USA: US General Accounting Office. Available at: http://161.203.16.4/d24t8/141456.pdf (Accessed 10.10.13).
- Anon. (2007). Toxicity Testing for the 21st Century: A Vision and a Strategy, 216pp. Washington, DC, USA: National Academies Press.
Cited by
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
“Furthermore, even in the presence of animal toxicity, LRs were extremely inconsistent and varied considerably for different classes of drugs (13,52).”
BackgroundState-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology
Alépée, N. (2014) · ALTEX · doi:10.14573/altex.1406111 · Cited by 217
Monticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K., & Kadambi, V. J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.006 · Cited by 186
An analysis of the use of animal models in predicting human toxicology and drug safety
Bailey, J., Thew, M., & Balls, M. (2014) · Alternatives to Laboratory Animals · doi:10.1177/026119291404200306 · Cited by 182
Self-citationA multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing
Dehne, E., Ramme, A. P., Terrasso, A. P., Serra, M., Alves, P. M., Brito, C., Sakharov, D. A., Tonevitsky, A., Lauster, R., & Marx, U. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.02.002 · Cited by 165
Metadata
- Authors
- Bailey, J., Thew, M., & Balls, M.
- Affiliations
- British Union for the Abolition of Vivisection (BUAV), London, UK
- Fund for the Replacement of Animals in Medical Experiments (GB)
- Corresponding author
- Bailey, Jarrod
- ORCID
- Bailey, Jarrod
- Venue
- Alternatives to Laboratory Animals
- Publisher
- SAGE Publications
- Published
- 2013-11
- Volume
- 41
- Issue
- 5
- Pages
- 335-350
- ISSN
- 0261-1929 (ISSN-L)
- 2632-3559
- OpenAlex
- W2187141863
- Cited by
- 71
- References
- 55
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 7 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 8
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Alternatives to Laboratory Animals (publishedVersion)
- PubMed (publishedVersion)
- WBI Studies Repository (submittedVersion)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- dogs, preclinical drug development, drug safety, likelihood ratios, adverse drug reactions, animal-to-human extrapolation, non-rodent animal models, MedDRA, alternatives to animal testing
- MeSH terms
- Animals, Dogs, Drug Evaluation, Preclinical, Humans, Likelihood Functions, Animal Use Alternatives, Animal Experimentation, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.